Page last updated: 2024-11-10

cp 99994

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311057
CHEMBL ID441225
SCHEMBL ID1282327
MeSH IDM0215633

Synonyms (43)

Synonym
gtpl2102
cp 99,994
(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine
3-piperidinamine, n-((2-methoxyphenyl)methyl)-2-phenyl-, (2s,3s)-
3-(2-methoxybenzylamino)-2-phenylpiperidine
3-piperidinamine, n-((2-methoxyphenyl)methyl)-2-phenyl-, (2s-cis)-
cp 99994
cp-99,994
cp99994
CHEMBL441225 ,
(2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine
cp 100,263
cp-100,263
136982-36-0
cp-99994
(-) (2-methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
(2-methoxy-benzyl)-((1r,4s)-2-phenyl-piperidin-4-yl)-amine
bdbm50000041
(2s,3s)-n-(2-methoxybenzyl)-2-phenylpiperidin-3-amine
(-)-(2-methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
(2-methoxy-benzyl)-((2s,3s)-2-phenyl-piperidin-3-yl)-amine
(+/-)(2-methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
tritiated-(2-methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
(+)-(2-methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
(2s,3s)-3-(2-methoxy-benzyloxy)-2-phenyl-piperidine
(+) (2-methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
5km4qa7rzc ,
unii-5km4qa7rzc
SCHEMBL1282327
DTQNEFOKTXXQKV-HKUYNNGSSA-N
(2s, 3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine
(2s,3s)-3-(2-methoxybenzyl)amino-2-phenylpiperdine
cis-3-(2-methoxybenzylamino)-2-phenylpiperidine
(2s,3s)-3-(2-methoxybenzyl)amino-2-phenylpiperidine
3-piperidinamine, n-[(2-methoxyphenyl)methyl]-2-phenyl-, (2s,3s)-
NCGC00370844-01
(+)-cp-99994
3-[(2-methoxybenzyl)amino]-2-phenyl-piperidine
(2s,3s)-cis-3-(2-methoxybenzylamino)-2-phenylpiperidine
DTXSID10929612
Q27076905
(2~{s},3~{s})-~{n}-[(2-methoxyphenyl)methyl]-2-phenyl-piperidin-3-amine
NCGC00370844-03

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic evaluation of SB 223412 in rat and dog indicated low plasma clearance, oral bioavailability and high and sustained plasma concentrations after 4 to 8 mg/kg oral dosages."( Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Brawner, ME; Elshourbagy, NA; Foley, JJ; Giardina, GA; Griswold, DE; Hay, DW; Martin, LD; Medhurst, AD; Potts, W; Sarau, HM; Schmidt, DB; Webb, EF, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
" Tetrazole 19 inhibits radiation-induced emesis in the ferret with high potency when administered both subcutaneously and orally, has a long duration of action, and has high oral bioavailability in the dog."( Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
Armour, DR; Bays, DE; Evans, B; Giblin, GM; Heron, N; Hubbard, T; Liang, K; Middlemiss, D; Mordaunt, J; Ward, P, 1995
)
0.29
" Pharmacokinetic evaluation of SB 223412 in rat and dog indicated low plasma clearance, oral bioavailability and high and sustained plasma concentrations after 4 to 8 mg/kg oral dosages."( Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Brawner, ME; Elshourbagy, NA; Foley, JJ; Giardina, GA; Griswold, DE; Hay, DW; Martin, LD; Medhurst, AD; Potts, W; Sarau, HM; Schmidt, DB; Webb, EF, 1997
)
0.3
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Thus, we have compared the actions of the selective neurokinin 1 (NK1) (CP-99,994) and neurokinin 2 (NK2) (SR-48,968) receptor antagonists against dose-response curves (DRC) induced by intravenously administered substance P (SP), neurokinin A (NKA), neurokinin B (NKB), beta Ala8-NKA (4-10),Sar9-Met(O2)11SP, and single dose (intravenous) challenge with resiniferatoxin (RTX), a capsaicin-like sensory neurotoxin, leukotriene D4 (LTD4) and antigen."( NK1 and NK2 receptors mediate tachykinin and resiniferatoxin-induced bronchospasm in guinea pigs.
Champion, E; Foulon, DM; Jones, TR; Masson, P; Rodger, IW, 1993
)
0.29
" In its presence, the dose-response curve for RP 67580 was dose-dependently shifted to the left."( The glycine B receptor partial agonist, (+)-HA966, enhances induction of antinociception by RP 67580 and CP-99,994.
Millan, MJ; Seguin, L, 1994
)
0.29
" Guinea-pigs were dosed subcutaneously (s."( Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat.
Bolser, DC; DeGennaro, FC; Hey, JA; McLeod, RL; O'Reilly, S, 1997
)
0.3
" Capsaicin (10(-6) M) caused relaxation and desensitization that was overcome by long recovery periods and substance P dosing (10(-8) M)."( Activation of non-adrenergic non-cholinergic inhibitory pathways by endogenous and exogenous tachykinins in the ferret lower oesophageal sphincter.
Blackshaw, LA; Lynn, PA; Smid, SD; Templeman, R, 1998
)
0.3
" Emesis induced by RS14203 exhibited a dose-response relationship but no such relationship was seen for R-rolipram or CT-2450."( Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret.
Choudhury, I; Robichaud, A; Rodger, IW; Tattersall, FD, 1999
)
0.3
" Ablation of peripheral NK1 receptors attenuated the ability of GR73632 to induce a maximal frequency of emesis and shifted its percent animals vomiting dose-response curve to the right."( Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
Abad, J; Darmani, NA; Ramirez, J; Ray, AP; Thrush, GR; Wang, Y, 2008
)
0.35
" The antiemetic dose-response curves of tropisetron against both emetogens were U-shaped probably because larger doses of this antagonist behave as a partial agonist."( Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).
Alkam, T; Amos, B; Chebolu, S; Darmani, NA, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency1.06840.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00060.00011.617910.0000AID242405
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.00060.00011.700010.0000AID242405
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)0.00060.00011.700010.0000AID242405
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)0.00060.00011.700010.0000AID242405
Substance-P receptorHomo sapiens (human)IC50 (µMol)0.00040.00000.09526.8130AID208265; AID208269; AID208420; AID208421; AID208425; AID208593; AID242405; AID303659; AID599136
Substance-P receptorHomo sapiens (human)Ki2.50020.00000.79368.7470AID208577; AID208598
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346346Human NK1 receptor (Tachykinin receptors)2002European journal of pharmacology, Aug-23, Volume: 450, Issue:2
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
AID1346346Human NK1 receptor (Tachykinin receptors)1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
AID208420Displacement of [125I]-labeled SP from human Tachykinin receptor 1 expressed in CHO cells1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
AID76984Inhibition of substance P-induced dermal plasma extravasation in the guinea pig 1 hr after oral dose1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID25855Physicochemical property pKa of piperdine amine was determined1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
AID71918Effect on heart rate of substance P antagonist was determined as change heart rate in the anesthetized ferret at 3 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID77003SP-induced dermal inflammation assay in guinea pig after peroral administration followed by SP challenge id after 1 hr1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
AID225484Inhibition of plasma dura matter of the rat after intravenous administration1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists.
AID76673Inhibition of aerosolized capsaicin-induced plasma protein extravasation in guinea pig ureter by peroral dose1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.
AID144529Evaluated for the binding affinity towards NK1 receptor in the striatal membranes of guinea pig1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis, in vitro binding profile, and autoradiographic analysis of [3H]-cis-3-[(2-methoxybenzyl)amino]-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand.
AID208421Displacement of [125 I]-Tyr8 SP from the cloned human Tachykinin receptor 1 expressed in CHO cells1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists.
AID59917In vitro metabolic turnover (% parent lost) after exposure to dog hepatic microsomes (hepatic first pass metabolism)1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID76671Compound tested for SP-induced plasma extravasation in guinea pig perorally1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.
AID71916Effect on heart rate of substance P antagonist was determined as change heart rate in the anesthetized ferret at 0.3 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID208593Binding affinity was measured against the Tachykinin receptor 1 in human IM-9 cells using [3H]SP as ligand.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor.
AID208110In vitro binding affinity against Tachykinin receptor 1 in guinea pig ileum using organ bath assay2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.
AID76672Inhibition of aerosolized capsaicin-induced plasma protein extravasation in guinea pig lung by peroral dose1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.
AID76973Inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea on peroral administration1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine.
AID208577In vitro binding affinity for the Tachykinin receptor 1 in human IM-9 cell using [125I]BH-SP of the compound.1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Discovery of a potent substance P antagonist: recognition of the key molecular determinant.
AID72230Maximum change in the mean arterial blood pressure in the anesthetized ferret of substance P at 3 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID72204Compound was evaluated in vivo for its antiemetic activity in ferret, which was administered subcutaneously immediately after (0 ptt) induction of emesis1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID242405Inhibition of substance P binding to Tachykinin receptor 1 in Chinese hamster ovary cells2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model.
AID599136Antagonist activity at NK1 receptor2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.
AID25854Physicochemical property pKa of benzyl amine was determined1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
AID76972Inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea on intravenous administration1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine.
AID222278Inhibition of SP- induced dermal guinea pig after peroral administration1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists.
AID208425Inhibition of [125I]-BH-Substance P binding to tachykinin receptor 1 in human IM-9 cells1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine.
AID71917Effect on heart rate of substance P antagonist was determined as change heart rate in the anesthetized ferret at 1 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID71915Effect on heart rate of substance P antagonist was determined as change heart rate in the anesthetized ferret at 0.1 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID208598Binding affinity to Tachykinin receptor 1 stably expressed in chinese hamster ovary (CHO) cells1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID18149Oral bioavailability in dog1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID95576Inhibition of [3H]diltiazem binding to L-type [Ca2+] channel in rabbit skeletal muscle1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
AID72229Maximum change in the mean arterial blood pressure in the anesthetized ferret of substance P at 1 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID19409Lipophilicity1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID72203Compound was evaluated in vivo for its antiemetic activity in ferret, which was administered subcutaneously 90 minutes before (90 ptt) induction of emesis;>80% inhibition observed1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID208269Binding affinity against human Tachykinin receptor 1 expressed in CHO cells was measured by its ability to displace [125I]- Tyr-8 substance P.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID303659Displacement of [3H]substance P from NK1 human receptor expressed in IM9 cells2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist.
AID72228Maximum change in the mean arterial blood pressure in the anesthetized ferret of substance P at 0.3 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID208095Compound was evaluated for its ex vivo binding affinity towards Tachykinin receptor 1 measured 15 minutes post administration to gerbil1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID15891Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
AID219077Effects administered perorally on writhing and vomiting response in ferrets induced by 10 mg/kg iv dose of cisplatin1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists.
AID72227Maximum change in the mean arterial blood pressure in the anesthetized ferret of substance P at 0.1 mg/Kg intravenous bolus1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan.
AID45631Displacement of [3H]diltiazem from rabbit skeletal muscle calcium channel1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists.
AID208265Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.
AID76696Compound was tested for blockade of locomotor activity in the guinea pig elicited by icv administered Sar9Met(O2)-SP1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (227)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's121 (53.30)18.2507
2000's82 (36.12)29.6817
2010's21 (9.25)24.3611
2020's3 (1.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.87%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other229 (99.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]